Skip to main content
Top
Published in: Respiratory Research 1/2010

Open Access 01-12-2010 | Research

Nrf2 protects against pulmonary fibrosis by regulating the lung oxidant level and Th1/Th2 balance

Authors: Norihiro Kikuchi, Yukio Ishii, Yuko Morishima, Yuichi Yageta, Norihiro Haraguchi, Ken Itoh, Masayuki Yamamoto, Nobuyuki Hizawa

Published in: Respiratory Research | Issue 1/2010

Login to get access

Abstract

Background

Pulmonary fibrosis is a progressive and lethal disorder. Although the precise mechanisms of pulmonary fibrosis are not fully understood, oxidant/antioxidant and Th1/Th2 balances may play an important role in many of the processes of inflammation and fibrosis. The transcription factor Nrf2 acts as a critical regulator for various inflammatory and immune responses by controlling oxidative stress. We therefore investigated the protective role of Nrf2 against the development of pulmonary fibrosis.

Methods

To generate pulmonary fibrosis, both wild-type C57BL/6 mice and Nrf2-deficient mice of the same background were administered bleomycin intratracheally.

Results

The survival of Nrf2-deficient mice after bleomycin administration was significantly lower than that of wild-type mice. The degree of bleomycin-induced initial pulmonary inflammation and pulmonary fibrosis was much more severe in Nrf2-deficient mice than in wild-type mice. The expression of antioxidant enzymes and phase II detoxifying enzymes was significantly reduced in the lungs of Nrf2-deficient mice, concomitant with an elevation of lung 8-isoprostane level, compared with wild-type mice. The expression of Th2 cytokines, such as interleukin-4 and interleukin-13, was significantly elevated in the lungs of Nrf2-deficient mice with an increase in the number of Th2 cells that express GATA-binding protein 3.

Conclusions

The results indicated that Nrf2 protects against the development of pulmonary fibrosis by regulating the cellular redox level and lung Th1/Th2 balance. Thus, Nrf2 might be an important genetic factor in the determination of susceptibility to pulmonary fibrosis.
Literature
1.
go back to reference American Thoracic Society: Idiopathic pulmonary fibrosis: diagnosis and treatment: international concensus statement. Am J Respir Crit Care Med 2000, 161:646–664.CrossRef American Thoracic Society: Idiopathic pulmonary fibrosis: diagnosis and treatment: international concensus statement. Am J Respir Crit Care Med 2000, 161:646–664.CrossRef
2.
go back to reference Gal AA, Staton GW: Current concepts in the classification of interstitial lung disease. Am J Clin Pathol 2005,123(suppl):S67-S81.PubMed Gal AA, Staton GW: Current concepts in the classification of interstitial lung disease. Am J Clin Pathol 2005,123(suppl):S67-S81.PubMed
3.
4.
go back to reference Barqaqli E, Olivieri C, Bennett D, Prasse A, Muller-Quernheim J, Rottoli P: Oxidative stress in the pathogenesis of diffuse lung diseases: a review. Respir Med 2009, 103:1245–1256.CrossRef Barqaqli E, Olivieri C, Bennett D, Prasse A, Muller-Quernheim J, Rottoli P: Oxidative stress in the pathogenesis of diffuse lung diseases: a review. Respir Med 2009, 103:1245–1256.CrossRef
5.
go back to reference Kinnula VL, Fattman CL, Tan RJ, Oury TD: Oxidative stress in pulmonary fibrosis: a possible role for redox modulatory therapy. Am J Respir Crit Care Med 2005, 172:417–422.CrossRefPubMedPubMedCentral Kinnula VL, Fattman CL, Tan RJ, Oury TD: Oxidative stress in pulmonary fibrosis: a possible role for redox modulatory therapy. Am J Respir Crit Care Med 2005, 172:417–422.CrossRefPubMedPubMedCentral
6.
go back to reference Rahman I, Biswas SK, Kode A: Oxidant and antioxidant balance in the airways and airway diseases. Eur J Pharmacol 2006, 533:222–239.CrossRefPubMed Rahman I, Biswas SK, Kode A: Oxidant and antioxidant balance in the airways and airway diseases. Eur J Pharmacol 2006, 533:222–239.CrossRefPubMed
7.
go back to reference Wang Y, Feinstein SI, Manevich Y, Ho YS, Fisher AB: Peroxiredoxin 6 gene-targeted mice show increased lung injury with paraquat-induced oxidative stress. Antioxid Redox Signal 2006, 8:229–237.CrossRefPubMed Wang Y, Feinstein SI, Manevich Y, Ho YS, Fisher AB: Peroxiredoxin 6 gene-targeted mice show increased lung injury with paraquat-induced oxidative stress. Antioxid Redox Signal 2006, 8:229–237.CrossRefPubMed
8.
go back to reference Otterbein LE, Mantel LL, Choi AM: Carbon monoxide provides protection against hyperoxic lung injury. Am J Physiol 1999, 276:L688-L694.PubMed Otterbein LE, Mantel LL, Choi AM: Carbon monoxide provides protection against hyperoxic lung injury. Am J Physiol 1999, 276:L688-L694.PubMed
9.
go back to reference Meyer A, Buhl R, Maqnussen H: The effect of oral N-acetylcysteine on lung glutathione levels in idiopathic pulmonary fibrosis. Eur Respir J 1994, 7:431–436.CrossRefPubMed Meyer A, Buhl R, Maqnussen H: The effect of oral N-acetylcysteine on lung glutathione levels in idiopathic pulmonary fibrosis. Eur Respir J 1994, 7:431–436.CrossRefPubMed
10.
go back to reference Furuie H, Yamasaki H, Suga M, Ando M: Altered accessory cell function of alveolar macrophages: a possible mechanism for induction of Th2 secretory profile in idiopathic pulmonary fibrosis. Eur Respir J 1997, 10:787–794.PubMed Furuie H, Yamasaki H, Suga M, Ando M: Altered accessory cell function of alveolar macrophages: a possible mechanism for induction of Th2 secretory profile in idiopathic pulmonary fibrosis. Eur Respir J 1997, 10:787–794.PubMed
11.
go back to reference Hancock A, Armstrong L, Gama R, Millar A: Production of interleukin 13 by alveolar macrophages from normal and fibrotic lung. Am J Respir Cell Mol Biol 1998, 18:60–65.CrossRefPubMed Hancock A, Armstrong L, Gama R, Millar A: Production of interleukin 13 by alveolar macrophages from normal and fibrotic lung. Am J Respir Cell Mol Biol 1998, 18:60–65.CrossRefPubMed
12.
go back to reference Kunkel SL, Lukacs NW, Strieter RM, Chensue SW: Th1 and Th2 responses regulate experimental lung granuloma development. Sarcoidosis Vasc Diffuse Lung Dis 1996, 13:120–128.PubMed Kunkel SL, Lukacs NW, Strieter RM, Chensue SW: Th1 and Th2 responses regulate experimental lung granuloma development. Sarcoidosis Vasc Diffuse Lung Dis 1996, 13:120–128.PubMed
13.
go back to reference Itoh K, Chiba T, Takahashi S, Ishii T, Igarashi K, Katoh Y, Oyake T, Hayashi N, Satoh K, Hatayama I, Yamamoto M, Nabeshima Y: An Nrf2/small Maf heterodimer mediates the induction of phase II detoxifying enzyme genes through antioxidant response elements. Biochem Biophys Res Commun 1997, 236:313–322.CrossRefPubMed Itoh K, Chiba T, Takahashi S, Ishii T, Igarashi K, Katoh Y, Oyake T, Hayashi N, Satoh K, Hatayama I, Yamamoto M, Nabeshima Y: An Nrf2/small Maf heterodimer mediates the induction of phase II detoxifying enzyme genes through antioxidant response elements. Biochem Biophys Res Commun 1997, 236:313–322.CrossRefPubMed
14.
go back to reference Ishii T, Itoh K, Takahashi S, Sato H, Yanagawa Y, Katoh Y, Bannai S, Yamamoto M: Transcription factor Nrf2 coordinately regulates a group of oxidative stress-inducible genes in macrophages. J Biol Chem 2000, 275:16023–16029.CrossRefPubMed Ishii T, Itoh K, Takahashi S, Sato H, Yanagawa Y, Katoh Y, Bannai S, Yamamoto M: Transcription factor Nrf2 coordinately regulates a group of oxidative stress-inducible genes in macrophages. J Biol Chem 2000, 275:16023–16029.CrossRefPubMed
16.
go back to reference Cho HY, Jedlicka AE, Reddy SP, Kensler TW, Yamamoto M, Zhang LY, Kleeberger SR: Role of NRF2 in protection against hyperoxic lung injury in mice. Am J Respir Cell Mol Biol 2002, 26:175–182.CrossRefPubMed Cho HY, Jedlicka AE, Reddy SP, Kensler TW, Yamamoto M, Zhang LY, Kleeberger SR: Role of NRF2 in protection against hyperoxic lung injury in mice. Am J Respir Cell Mol Biol 2002, 26:175–182.CrossRefPubMed
17.
go back to reference Cho HY, Reddy SP, Yamamoto M, Kleeberger SR: The transcription factor NRF2 protects against pulmonary fibrosis. FASEB J 2004, 18:1258–1260.PubMed Cho HY, Reddy SP, Yamamoto M, Kleeberger SR: The transcription factor NRF2 protects against pulmonary fibrosis. FASEB J 2004, 18:1258–1260.PubMed
18.
go back to reference Walters D, Cho HY, Kleeberger SR: Oxidative stress and antioxidants in the pathogenesis of pulmonary fibrosis: a potential role for Nrf2. Antioxid Redox Signal 2008, 10:321–332.CrossRefPubMed Walters D, Cho HY, Kleeberger SR: Oxidative stress and antioxidants in the pathogenesis of pulmonary fibrosis: a potential role for Nrf2. Antioxid Redox Signal 2008, 10:321–332.CrossRefPubMed
19.
go back to reference Williams MA, Rangasamy T, Bauer SM, Killedar S, Karp M, Kensler TW, Yamamoto M, Breysse P, Biswal S, Georas SN: Disruption of the transcription factor Nrf2 promotes pro-oxidative dendritic cells that stimulate Th2-like immunoresponsiveness upon activation by ambient particulate matter. J Immunol 2008, 181:4545–4559.CrossRefPubMedPubMedCentral Williams MA, Rangasamy T, Bauer SM, Killedar S, Karp M, Kensler TW, Yamamoto M, Breysse P, Biswal S, Georas SN: Disruption of the transcription factor Nrf2 promotes pro-oxidative dendritic cells that stimulate Th2-like immunoresponsiveness upon activation by ambient particulate matter. J Immunol 2008, 181:4545–4559.CrossRefPubMedPubMedCentral
20.
go back to reference Riedl MA, Nel AE: Importance of oxidative stress in the pathogenesis and treatment of asthma. Curr Opin Allergy Clin Immunol 2008, 8:49–56.CrossRefPubMed Riedl MA, Nel AE: Importance of oxidative stress in the pathogenesis and treatment of asthma. Curr Opin Allergy Clin Immunol 2008, 8:49–56.CrossRefPubMed
21.
22.
go back to reference Woessner LF: The determination of hydroxyproline in tissue and protein samples containing small proportions of this imino acid. Arch Biochem Biophys 1961, 93:440–447.CrossRefPubMed Woessner LF: The determination of hydroxyproline in tissue and protein samples containing small proportions of this imino acid. Arch Biochem Biophys 1961, 93:440–447.CrossRefPubMed
23.
go back to reference Murphy E, Shibuya K, Hosken N, Openshaw P, Maino V, Davis K, Murphy K, O'Garra A: Reversibility of T helper 1 and 2 populations is lost after long term stimulation. J Exp Med 1996, 183:901–913.CrossRefPubMed Murphy E, Shibuya K, Hosken N, Openshaw P, Maino V, Davis K, Murphy K, O'Garra A: Reversibility of T helper 1 and 2 populations is lost after long term stimulation. J Exp Med 1996, 183:901–913.CrossRefPubMed
24.
go back to reference Bassett DJP, Bowen-Kelly E, Brewster EL, Elbon CL, Reichenbaugh SS, Bunton T, Kerr JS: A reversible model of acute lung injury based on ozone exposure. Lung 1988, 166:355–369.CrossRefPubMed Bassett DJP, Bowen-Kelly E, Brewster EL, Elbon CL, Reichenbaugh SS, Bunton T, Kerr JS: A reversible model of acute lung injury based on ozone exposure. Lung 1988, 166:355–369.CrossRefPubMed
25.
go back to reference Kawai K, Akaza H: Bleomycin-induced pulmonary toxicity in chemotherapy for testicular cancer. Expert Opin Drug Saf 2003, 2:587–596.CrossRefPubMed Kawai K, Akaza H: Bleomycin-induced pulmonary toxicity in chemotherapy for testicular cancer. Expert Opin Drug Saf 2003, 2:587–596.CrossRefPubMed
26.
go back to reference Moore BB, Hogaboam CM: Murine model of pulmonary fibrosis. Am J Physiol Lung Cell Mol Physiol 2008, 294:L152–160.CrossRefPubMed Moore BB, Hogaboam CM: Murine model of pulmonary fibrosis. Am J Physiol Lung Cell Mol Physiol 2008, 294:L152–160.CrossRefPubMed
27.
go back to reference Burger RM, Peisach J, Blumberg WE, Horwitz SB: Ironbleomycin interactions with oxygen and oxygen analogues. J Biol Chem 1979, 254:10906–10912.PubMed Burger RM, Peisach J, Blumberg WE, Horwitz SB: Ironbleomycin interactions with oxygen and oxygen analogues. J Biol Chem 1979, 254:10906–10912.PubMed
28.
go back to reference Adamson IYR, Bowden DH: The pathogenesis of bleomycin-induced pulmonary fibrosis in mice. Am J Pathol 1974, 77:185–191.PubMedPubMedCentral Adamson IYR, Bowden DH: The pathogenesis of bleomycin-induced pulmonary fibrosis in mice. Am J Pathol 1974, 77:185–191.PubMedPubMedCentral
29.
go back to reference Weissler JC: Idiopathic pulmonary fibrosis: cellular and molecular pathogenesis. Am J Med Sci 1989, 297:92–104.CrossRef Weissler JC: Idiopathic pulmonary fibrosis: cellular and molecular pathogenesis. Am J Med Sci 1989, 297:92–104.CrossRef
30.
go back to reference Kobayashi A, Kang MI, Okawa H, Ohtsuji M, Zenke Y, Chiba T, Igarashi K, Yamamoto M: Oxidative stress sensor Keap1 functions as an adaptor for Cul3-based E3 ligase to regulate proteasomal degradation of Nrf2. Mol Cell Biol 2004, 24:7130–139.CrossRefPubMedPubMedCentral Kobayashi A, Kang MI, Okawa H, Ohtsuji M, Zenke Y, Chiba T, Igarashi K, Yamamoto M: Oxidative stress sensor Keap1 functions as an adaptor for Cul3-based E3 ligase to regulate proteasomal degradation of Nrf2. Mol Cell Biol 2004, 24:7130–139.CrossRefPubMedPubMedCentral
31.
go back to reference Zhang DD, Lo SC, Cross JV, Templeton DJ, Hannink M: Keap1 is a redox-regulated substrate adaptor protein for a Cul3-dependent ubiquitin ligase complex. Mol Cell Biol 2004, 24:10941–10953.CrossRefPubMedPubMedCentral Zhang DD, Lo SC, Cross JV, Templeton DJ, Hannink M: Keap1 is a redox-regulated substrate adaptor protein for a Cul3-dependent ubiquitin ligase complex. Mol Cell Biol 2004, 24:10941–10953.CrossRefPubMedPubMedCentral
32.
go back to reference Cho HY, Reddy SP, Kleeberger SR: Nrf2 defends the lung from oxidative stress. Antioxid Redox Signal 2006, 8:76–87.CrossRefPubMed Cho HY, Reddy SP, Kleeberger SR: Nrf2 defends the lung from oxidative stress. Antioxid Redox Signal 2006, 8:76–87.CrossRefPubMed
33.
go back to reference Sriram N, Kalayarasan S, Sudhandiran G: Enhancement of antioxidant defense system by epigallocatechin-3-gallate during bleomycin induced experimental pulmonary fibrosis. Biol Pharm Bull 2008, 31:1306–1311.CrossRefPubMed Sriram N, Kalayarasan S, Sudhandiran G: Enhancement of antioxidant defense system by epigallocatechin-3-gallate during bleomycin induced experimental pulmonary fibrosis. Biol Pharm Bull 2008, 31:1306–1311.CrossRefPubMed
34.
go back to reference Hoshino T, Nakamura H, Okamoto M, Kato S, Araya S, Nomiyama K, Oizumi K, Young HA, Aizawa H, Yodoi J: Redox-active protein thioredoxin prevents proinflammatory cytokine- or bleomycin-induced lung injury. Am J Respir Crit Care Med 2003, 168:1075–1083.CrossRefPubMed Hoshino T, Nakamura H, Okamoto M, Kato S, Araya S, Nomiyama K, Oizumi K, Young HA, Aizawa H, Yodoi J: Redox-active protein thioredoxin prevents proinflammatory cytokine- or bleomycin-induced lung injury. Am J Respir Crit Care Med 2003, 168:1075–1083.CrossRefPubMed
35.
go back to reference Liu X, Kohyama T, Wang H, Zhu YK, Wen FQ, Kim HJ, Romberger DJ, Rennard SI: Th2 cytokine regulation of type I collagen gel contraction mediated by human lung mesenchymal cells. Am J Physiol Lung Cell Mol Physiol 2002, 282:L1049–1056.CrossRefPubMed Liu X, Kohyama T, Wang H, Zhu YK, Wen FQ, Kim HJ, Romberger DJ, Rennard SI: Th2 cytokine regulation of type I collagen gel contraction mediated by human lung mesenchymal cells. Am J Physiol Lung Cell Mol Physiol 2002, 282:L1049–1056.CrossRefPubMed
36.
go back to reference Sempowski GD, Derdak S, Phipps RP: Interleukin-4 and interferon-gamma discordantly regulate collagen biosynthesis by functionally distinct lung fibroblast subsets. J Cell Physiol 1996, 167:290–296.CrossRefPubMed Sempowski GD, Derdak S, Phipps RP: Interleukin-4 and interferon-gamma discordantly regulate collagen biosynthesis by functionally distinct lung fibroblast subsets. J Cell Physiol 1996, 167:290–296.CrossRefPubMed
37.
go back to reference Postlethwaite AE, Holness MA, Katai H, Raghow R: Human fibroblasts synthesize elevated levels of extracellular matrix proteins in response to interleukin 4. J Clin Invest 1992, 90:1479–1485.CrossRefPubMedPubMedCentral Postlethwaite AE, Holness MA, Katai H, Raghow R: Human fibroblasts synthesize elevated levels of extracellular matrix proteins in response to interleukin 4. J Clin Invest 1992, 90:1479–1485.CrossRefPubMedPubMedCentral
38.
go back to reference Zheng DH, Flavell RA: The transcription factor GATA-3 is necessary and sufficient for Th2 cytokine gene expression in CD4 T cells. Cell 1997, 89:587–596.CrossRefPubMed Zheng DH, Flavell RA: The transcription factor GATA-3 is necessary and sufficient for Th2 cytokine gene expression in CD4 T cells. Cell 1997, 89:587–596.CrossRefPubMed
39.
go back to reference Takemoto N, Kamogawa Y, Lee HJ, Kuruta H, Arai K, O'Garra A, Arai N, Miyataka S: Chromatin remodeling at the IL4/IL13 intergenic regulatory region for Th2-specific cytokine gene cluster. J Immunol 2000, 165:6687–6691.CrossRefPubMed Takemoto N, Kamogawa Y, Lee HJ, Kuruta H, Arai K, O'Garra A, Arai N, Miyataka S: Chromatin remodeling at the IL4/IL13 intergenic regulatory region for Th2-specific cytokine gene cluster. J Immunol 2000, 165:6687–6691.CrossRefPubMed
40.
go back to reference Lee GR, Field PE, Flavell RA: Regulation of IL-4 gene expression by distal regulatory elements and GATA-3 at the chromatin level. Immunity 2001, 14:447–459.CrossRefPubMed Lee GR, Field PE, Flavell RA: Regulation of IL-4 gene expression by distal regulatory elements and GATA-3 at the chromatin level. Immunity 2001, 14:447–459.CrossRefPubMed
41.
go back to reference Kimura T, Ishii Y, Yoh K, Morishima Y, Iizuka T, Kiwamoto T, Matsuno Y, Homma S, Nomura A, Sakamoto T, Takahashi S, Sekizawa K: Overexpression of the transcription factor GATA-3 enhances the development of pulmonary fibrosis. Am J Pathol 2006, 169:96–104.CrossRefPubMedPubMedCentral Kimura T, Ishii Y, Yoh K, Morishima Y, Iizuka T, Kiwamoto T, Matsuno Y, Homma S, Nomura A, Sakamoto T, Takahashi S, Sekizawa K: Overexpression of the transcription factor GATA-3 enhances the development of pulmonary fibrosis. Am J Pathol 2006, 169:96–104.CrossRefPubMedPubMedCentral
42.
go back to reference Rangasamy T, Guo J, Mitzner WA, Roman J, Singh A, Fryer AD, Yamamoto M, Kensler TW, Tuder RM, Georas SN, Biswal S: Disruption of Nrf2 enhances susceptibility to severe airway inflammation and asthma in mice. J Exp Med 2005, 202:47–59.CrossRefPubMedPubMedCentral Rangasamy T, Guo J, Mitzner WA, Roman J, Singh A, Fryer AD, Yamamoto M, Kensler TW, Tuder RM, Georas SN, Biswal S: Disruption of Nrf2 enhances susceptibility to severe airway inflammation and asthma in mice. J Exp Med 2005, 202:47–59.CrossRefPubMedPubMedCentral
43.
go back to reference King MR, Ismail AS, Davis LS, Karp DR: Oxidative stress promotes polarization of human T cell differentiation toward a T helper 2 phenotype. J Immunol 2006, 176:2765–2772.CrossRefPubMed King MR, Ismail AS, Davis LS, Karp DR: Oxidative stress promotes polarization of human T cell differentiation toward a T helper 2 phenotype. J Immunol 2006, 176:2765–2772.CrossRefPubMed
44.
go back to reference Christman JW, Sadikot RT, Blackwell TS: The role of nuclear factor-kappa B in pulmonary diseases. Chest 2000, 117:1482–1487.CrossRefPubMed Christman JW, Sadikot RT, Blackwell TS: The role of nuclear factor-kappa B in pulmonary diseases. Chest 2000, 117:1482–1487.CrossRefPubMed
45.
go back to reference Pantano C, Reynaert NL, Vliet A, Janssen-Heininger YM: Redox-sensitive kinases of the nuclear factor-kappaB signaling pathway. Antioxid Redox Signal 2006, 8:1791–1806.CrossRefPubMed Pantano C, Reynaert NL, Vliet A, Janssen-Heininger YM: Redox-sensitive kinases of the nuclear factor-kappaB signaling pathway. Antioxid Redox Signal 2006, 8:1791–1806.CrossRefPubMed
46.
go back to reference Gloire G, Legrand-Poels S, Piette J: NF-κB activation by reactive oxygen species: fifteen years later. Biochem Pharmacol 2006, 72:1493–1505.CrossRefPubMed Gloire G, Legrand-Poels S, Piette J: NF-κB activation by reactive oxygen species: fifteen years later. Biochem Pharmacol 2006, 72:1493–1505.CrossRefPubMed
47.
go back to reference Ishii Y, Itoh K, Morishima Y, Kimura T, Kiwamoto T, Iizuka T, Hegab AE, Hosoya T, Nomura A, Sakamoto T, Yamamoto M, Sekizawa K: Transcription factor Nrf2 plays a pivotal role in protection against elastase-induced pulmonary inflammation and emphysema. J Immunol 2005, 175:6968–6975.CrossRefPubMed Ishii Y, Itoh K, Morishima Y, Kimura T, Kiwamoto T, Iizuka T, Hegab AE, Hosoya T, Nomura A, Sakamoto T, Yamamoto M, Sekizawa K: Transcription factor Nrf2 plays a pivotal role in protection against elastase-induced pulmonary inflammation and emphysema. J Immunol 2005, 175:6968–6975.CrossRefPubMed
48.
go back to reference Iizuka T, Ishii Y, Itoh K, Kiwamoto T, Kimura T, Matsuno Y, Morishima Y, Hegab AE, Homma S, Nomura A, Sakamoto T, Shimura M, Yoshida A, Yamamoto M, Sekizawa K: Nrf2-deficient mice are highly susceptible to cigarette smoke-induced emphysema. Genes Cells 2005, 10:1113–1125.CrossRefPubMed Iizuka T, Ishii Y, Itoh K, Kiwamoto T, Kimura T, Matsuno Y, Morishima Y, Hegab AE, Homma S, Nomura A, Sakamoto T, Shimura M, Yoshida A, Yamamoto M, Sekizawa K: Nrf2-deficient mice are highly susceptible to cigarette smoke-induced emphysema. Genes Cells 2005, 10:1113–1125.CrossRefPubMed
Metadata
Title
Nrf2 protects against pulmonary fibrosis by regulating the lung oxidant level and Th1/Th2 balance
Authors
Norihiro Kikuchi
Yukio Ishii
Yuko Morishima
Yuichi Yageta
Norihiro Haraguchi
Ken Itoh
Masayuki Yamamoto
Nobuyuki Hizawa
Publication date
01-12-2010
Publisher
BioMed Central
Published in
Respiratory Research / Issue 1/2010
Electronic ISSN: 1465-993X
DOI
https://doi.org/10.1186/1465-9921-11-31

Other articles of this Issue 1/2010

Respiratory Research 1/2010 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.